...
首页> 外文期刊>Oncology reports >Identification of potential prognostic long non-coding RNA signatures based on a competing endogenous RNA network in lung adenocarcinoma
【24h】

Identification of potential prognostic long non-coding RNA signatures based on a competing endogenous RNA network in lung adenocarcinoma

机译:基于肺腺癌竞争内源性RNA网络的潜在预后长非编码RNA签收的鉴定

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A number of experimental and computational studies have demonstrated the key roles of long non-coding RNAs (lncRNAs) acting as competing endogenous RNAs (ceRNAs) in the tumorigenesis of lung adenocarcinoma (LUAC). However, there remains a requirement for prognostic candidate biomarkers acting as ceRNAs for the prediction of overall survival in patients with LUAC. The main goal of the present study was to identify novel lncRNAs associated with LUAC overall survival and assess their prognostic values. The study analyzed coding RNA and ncRNA expression profiles of patients with LUAC by retrieving existing RNA-sequencing datasets from The Cancer Genome Atlas database, and 2,507 differentially expressed mRNAs, 1,633 lncRNAs and 113 miRNAs were screened from patients with LUAC compared with those of adjacent normal samples (P0.01 and |logFC|2). Of these LUAC-specific RNAs, 134 lncRNAs, 21 miRNAs and 34 mRNAs were used to build an lncRNA-mRNA-miRNA ceRNA network, among which 8 lncRNAs and 9 mRNAs were associated with overall survival in patients with LUAC by acting as ceRNAs. Next, an lncRNA-based prognostic signature was constructed by risk scoring approach based on the expression levels of 9 prognosis-associated lncRNAs using Cox's regression analysis. Moreover, the prognostic capacity of the 9-lncRNA signature was independent of known clinical prognostic factors. These results provide novel insight into the potential of lncRNA ceRNAs to be candidate biomarkers associated with LUAC overall survival.
机译:许多实验和计算研究表明,长期非编码RNA(LNCRNA)作为竞争内源RNA(CERNAS)的关键作用在肺腺癌(LUAC)的肿瘤内血液中的竞争内源性RNA(CERNAS)。然而,仍然需要作为CERNAS的预后候选生物标志物,以便预测LUAC患者的整体存活。本研究的主要目的是鉴定与Luac总存活相关的新型LNCRNA,并评估其预后值。通过从癌症基因组Atlas数据库中检索现有的RNA测序数据集和2,507个差异表达的MRNA,1,633LNCRNA和113 miRNA的研究分析了Luac患者的编码RNA和NCRNA表达谱,与Luac的患者与邻近正常的患者筛选样品(P& 0.01和|& 2)。在这些Luac特异性的RNA中,使用134LNCRNA,21 miRNA和34 mRNA来构建LNCRNA-mRNA-miRNA Cerna网络,其中8个LNCRNA和9 mRNA与Luac患者作为Cernas的患者的整体存活相关。接下来,通过使用COX回归分析的3例预后相关的LNCRNA的表达水平的风险评分方法构建基于LNCRNA的预后签名。此外,9-LNCRNA签名的预后能力与已知的临床预后因子无关。这些结果提供了对LNCRNA Cernas的潜力的新颖洞察力成为与Luac整体存活相关的候选生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号